Clinical-stage specialist ABVC BioPharma is planning to significantly expand its US botanical-based pharmaceutical manufacturing capacity.
This follows ABVC BioPharma's prior expansion initiatives in the country, which involved the acquisition of a $60m, clinical-stage, small-scale GMP-certified API processing and formulation development facility in California.
The latest $120m investment into its US manufacturing capabilities will aim to establish a fully-integrated pharmaceutical manufacturing and botanical production ecosystem in the US.
Through this investment, ABVC also hopes to make the US its global hub, focusing on both drug development and commercial production.
ABVC BioPharma's latest investment
Following the company's investment into its Californian pharmaceutical manufacturing facility, ABVC is planning to construct gigafactories within the US, which will aid the cultivation of botanical raw materials for pharmaceutical products.
By utilising vertical farming and hydroponic systems with AI-driven environmental monitoring and control, the biopharma company plans to cultivate 1,000 tonnes of high-value medicinal raw plants material per year.
The company also intends to design to facility to ensure cultivation sustainability, while also reducing material costs and enhancing quality,
According to ABVC, these projects will create 500 new jobs in the area — spanning across the research, manufacturing and quality control niches.
“With more than $100 million already invested, ABVC is fully focused on building world-class pharmaceutical and botanical production infrastructure in the US, which explains the anticipated additional investments,” explained CEO of ABVC.
“We aim to deliver high-quality, plant-based therapies to patients worldwide while creating a secure, sustainable and efficient global supply chain.”